Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance - 1st Edition - ISBN: 9780444532350, 9780080932682

Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance, Volume 172

1st Edition

Editors: Giuseppe Di Giovanni Vincenzo Di Matteo Ennio Esposito
Hardcover ISBN: 9780444532350
eBook ISBN: 9780080932682
Imprint: Elsevier Science
Published Date: 26th September 2008
Page Count: 688
Tax/VAT will be calculated at check-out
305.00
268.00
230.00
185.00
Unavailable
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


Table of Contents

  1. SEROTONIN-DOPAMINE INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM

  2. Serotonin-Dopamine Interaction: an overview E. Esposito, V. Di Matteo and G. Di Giovanni (Santa Maria Imbaro, Chieti and Palermo, Italy)

  3. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies V. Di Matteo, G. Di Giovanni, M. Pierucci and E. Esposito (Santa Maria Imbaro, Chieti and Palermo, Italy)

  4. Serotonin-Dopamine Interaction: electrophysiological evidence G. Di Giovanni, V. Di Matteo, M. Pierucci and E. Esposito (Palermo and Santa Maria Imbaro, Chieti, Italy

  5. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders U.M. D’Souza and I.W. Craig (London, UK)

  6. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA

  7. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment J. de Almeida, J.M. Palacios and G. Mengod (Barcelona, Spain)

  8. Alterations of dopamine and serotonin transmission in schizophrenia G. Remington (Toronto, ON, Canada)

  9. Serotonin and dopamine interactions in psychosis prevention N.M. Richtand and R.K. McNamara (Cincinnati, OH, USA)

  10. Role of serotonin and dopamine receptor binding in antipsychotic efficacy N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski and R.K. McNamara (Cincinnati, OH, USA)

  11. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems H.Y. Meltzer and M. Huang (Nashville, TN, USA)

  12. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis T. Kuroki, N. Nagao and T. Nakahara (Kanzaki, Japan)

  13. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders M.D. Wood and P.W. Wren (Harlow, UK)

  14. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION

  15. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease K.A. Michelsen, J. Prickaerts and H.W.M. Steinbusch (Maastricht, The Netherlands)

  16. Dynamics of the dopaminergic system as a key component to the understanding of depression G. Yadid and A. Friedman (Ramat-Gan, Israel)

  17. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression K.A. Berg, J.A. Harvey, U. Spampinato and W.P. Clarke (San Antonio, TX, Philadelphia, PA, USA and Bordeaux, France)

  18. The role of dopamine and serotonin in suicidal behaviour and aggression E. Ryding, M. Lindström and L.Träskman-Bendz (Stockholm, Sweden)

  19. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION

  20. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse M.J. Bubar and K.A. Cunningham (Galveston, TX, USA)

  21. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour R.J. Carey, J.P. Huston and C.P. Müller (Dusseldorf, Germany and London, UK)

  22. Serotonin receptors as potential targets for modulation of nicotine use and dependence P.J. Fletcher, A. Dzung Lê and G.A. Higgins (Toronto, ON, Canada)

  23. Dopamine/Serotonin releasers as medications for stimulant addictions R.B. Rothman, B.E. Blough and M.H. Baumann (Baltimore, MD and Triangle Park, NC, USA)

  24. PTEN-5-HT2C coupling: A new target for treating drug addiction J.-C. Maillet, Y. Zhang, X. Li, X. Zhang (Ottawa, ON, Canada)

  25. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS

  26. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno and G. Di Giovanni (Santa Maria Imbaro, Chieti, and Palermo, Italy)

  27. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias M. Carta, T. Carlsson, A. Muňoz, D. Kirik and A. Björklund (Lund, Sweden)

  28. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy S.H. Fox, R. Chuang and J.M. Brotchie (Toronto, ON, Canada)

  29. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome| T.D.L. Steeves and S.H.Fox (Toronto, ON, Canada)

  30. SEROTONIN-DOPAMINE INTERACTIONS IN ATTENTIONAL PROCESSES, LEARNING AND MEMORY

  31. Serotonergic and dopaminergic modulation of attentional processes V. Boulougouris and EL. Tsaltas (Cambridge, UK and Athens, Greece)

  32. Dopamine-serotonin interactions in attention-deficit/hyperactivity disorder (ADHD) R.D. Oades (Essen, Germany)

  33. Serotonin/dopamine interaction in learning M.E. Olvera-Cortés, P. Anguiano-Rodríguez, M.Á.López-Vázquez, J.M. C. Alfaro (Morelia, Mich., Mexico)

  34. Serotonin-dopamine interaction in memory formation I. González-Burgos and A. Feria-Velasco (Guadalajara, Jal. Mexico)

  35. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking J.M. Monti and H. Jantos (Montevideo, Uruguay)


Description

  1. SEROTONIN-DOPAMINE INTERACTIONS IN THE CENTRAL NERVOUS SYSTEM

  2. Serotonin-Dopamine Interaction: an overview E. Esposito, V. Di Matteo and G. Di Giovanni (Santa Maria Imbaro, Chieti and Palermo, Italy)

  3. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies V. Di Matteo, G. Di Giovanni, M. Pierucci and E. Esposito (Santa Maria Imbaro, Chieti and Palermo, Italy)

  4. Serotonin-Dopamine Interaction: electrophysiological evidence G. Di Giovanni, V. Di Matteo, M. Pierucci and E. Esposito (Palermo and Santa Maria Imbaro, Chieti, Italy

  5. Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders U.M. D’Souza and I.W. Craig (London, UK)

  6. SEROTONIN-DOPAMINE INTERACTIONS IN SCHIZOPHRENIA

  7. Distribution of 5-HT and DA receptors in primate prefrontal cortex: implications for pathophysiology and treatment J. de Almeida, J.M. Palacios and G. Mengod (Barcelona, Spain)

  8. Alterations of dopamine and serotonin transmission in schizophrenia G. Remington (Toronto, ON, Canada)

  9. Serotonin and dopamine interactions in psychosis prevention N.M. Richtand and R.K. McNamara (Cincinnati, OH, USA)

  10. Role of serotonin and dopamine receptor binding in antipsychotic efficacy N.M. Richtand, J.A. Welge, A.D. Logue, P.E. Keck, Jr., S.M. Strakowski and R.K. McNamara (Cincinnati, OH, USA)

  11. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems H.Y. Meltzer and M. Huang (Nashville, TN, USA)

  12. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis T. Kuroki, N. Nagao and T. Nakahara (Kanzaki, Japan)

  13. Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders M.D. Wood and P.W. Wren (Harlow, UK)

  14. SEROTONIN-DOPAMINE INTERACTIONS IN DEPRESSION

  15. The dorsal raphe nucleus and serotonin —implications for neuroplasticity linked to major depression and Alzheimer’s disease K.A. Michelsen, J. Prickaerts and H.W.M. Steinbusch (Maastricht, The Netherlands)

  16. Dynamics of the dopaminergic system as a key component to the understanding of depression G. Yadid and A. Friedman (Ramat-Gan, Israel)

  17. Physiological and therapeutic relevance of constitutive activity of 5-HT2A and 5-HT2C receptors for the treatment of depression K.A. Berg, J.A. Harvey, U. Spampinato and W.P. Clarke (San Antonio, TX, Philadelphia, PA, USA and Bordeaux, France)

  18. The role of dopamine and serotonin in suicidal behaviour and aggression E. Ryding, M. Lindström and L.Träskman-Bendz (Stockholm, Sweden)

  19. SEROTONIN-DOPAMINE INTERACTIONS IN DRUG ADDICTION

  20. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse M.J. Bubar and K.A. Cunningham (Galveston, TX, USA)

  21. Pharmacological inhibition of dopamine- and serotonin activity blocks spontaneous and cocaine-activated behaviour R.J. Carey, J.P. Huston and C.P. Müller (Dusseldorf, Germany and London, UK)

  22. Serotonin receptors as potential targets for modulation of nicotine use and dependence P.J. Fletcher, A. Dzung Lê and G.A. Higgins (Toronto, ON, Canada)

  23. Dopamine/Serotonin releasers as medications for stimulant addictions R.B. Rothman, B.E. Blough and M.H. Baumann (Baltimore, MD and Triangle Park, NC, USA)

  24. PTEN-5-HT2C coupling: A new target for treating drug addiction J.-C. Maillet, Y. Zhang, X. Li, X. Zhang (Ottawa, ON, Canada)

  25. SEROTONIN-DOPAMINE INTERACTIONS IN MOTOR DISORDERS

  26. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders V. Di Matteo, M. Pierucci, E. Esposito, G. Crescimanno, A. Benigno and G. Di Giovanni (Santa Maria Imbaro, Chieti, and Palermo, Italy)

  27. Serotonin-Dopamine interaction in the induction and maintenance of LDOPA-induced dyskinesias M. Carta, T. Carlsson, A. Muňoz, D. Kirik and A. Björklund (Lund, Sweden)

  28. Parkinson’s disease – opportunities for novel therapeutics to reduce the problems of levodopa therapy S.H. Fox, R. Chuang and J.M. Brotchie (Toronto, ON, Canada)

  29. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome| T.D.L. Steeves and S.H.Fox (Toronto, ON, Canada)

  30. SEROTONIN-DOPAMINE INTERACTIONS IN ATTENTIONAL PROCESSES, LEARNING AND MEMORY

  31. Serotonergic and dopaminergic modulation of attentional processes V. Boulougouris and EL. Tsaltas (Cambridge, UK and Athens, Greece)

  32. Dopamine-serotonin interactions in attention-deficit/hyperactivity disorder (ADHD) R.D. Oades (Essen, Germany)

  33. Serotonin/dopamine interaction in learning M.E. Olvera-Cortés, P. Anguiano-Rodríguez, M.Á.López-Vázquez, J.M. C. Alfaro (Morelia, Mich., Mexico)

  34. Serotonin-dopamine interaction in memory formation I. González-Burgos and A. Feria-Velasco (Guadalajara, Jal. Mexico)

  35. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking J.M. Monti and H. Jantos (Montevideo, Uruguay)

Key Features

  • Provides an understanding of the interaction between Serotonin and Dopamine.
  • Appeals equally to specialists, general practitioners, students and researchers.
  • Contributes to the debate on new pharmacological approaches to several psychopathological states
  • Gives a comprehensive anatomical description plus the physiology and pharmacology of dopaminergic and serotonergic systems
  • Singles out neuropsychiatric and suggests new therapeutic approaches.

Readership

Clinical Psychiatrists, Primary Care Physicians, and specialists in the behavioral health community. Also Graduate students and researchers involved with serotonergic and dopaminergic systems. Possibly Pharmaceutical companies who market dopaminergic and serotonergic drugs


Details

No. of pages:
688
Language:
English
Copyright:
© Elsevier Science 2008
Published:
Imprint:
Elsevier Science
eBook ISBN:
9780080932682
Hardcover ISBN:
9780444532350

About the Editors

Giuseppe Di Giovanni Editor

Affiliations and Expertise

Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, ‘‘G. Pagano’’, Universita` di Palermo, Italy

Vincenzo Di Matteo Editor

Affiliations and Expertise

Istituto di Ricerche Farmacologiche Mario Negri, Italy

Ennio Esposito Editor

Affiliations and Expertise

Istituto di Ricerche Farmacologiche Mario Negri, Italy